公开(公告)号：US20090258826A1

公开(公告)日：2009-10-15

申请号：US12154468

申请日：2008-05-23

申请人： Wayne A. Froland ,  Drew N. Kelner ,  Michael L. Dumas ,  Clark Pan ,  James Whelan ,  Yu-chang John Wang ,  Wei Wang

发明人： Wayne A. Froland ,  Drew N. Kelner ,  Michael L. Dumas ,  Clark Pan ,  James Whelan ,  Yu-chang John Wang ,  Wei Wang

IPC分类号： A61K38/17 ,  C07K14/47 ,  C07H21/00 ,  C12N15/63 ,  C12N5/10 ,  C12P21/02 ,  C07K16/18 ,  A61P3/10 ,  A61K31/711

CPC分类号： C07K14/70503 ,  A61K38/00 ,  C07K14/57563

摘要： This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides are shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptides of this invention are also stable in formulation and have long half-lives. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VPAC2-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.

摘要翻译： 本发明提供了在体内作为VPAC2受体的激动剂起作用的新型肽。 显示这些胰岛素促分泌素多肽比葡萄糖攻击时的对照降低体内血糖。 本发明的多肽在制剂中也是稳定的并且具有长的半衰期。 本发明的肽为具有降低的内源性胰岛素分泌的患者特别是2型糖尿病患者提供了新的疗法。 特别地，本发明是选自VPAC2相关多肽的特定组的多肽或其功能等同物。 本发明还涉及一种治疗哺乳动物代谢疾病的方法，包括向所述哺乳动物施用治疗有效量的胰岛素促分泌肽。 还公开了制备重组体和合成肽的方法。

公开(公告)号：US07378494B2

公开(公告)日：2008-05-27

申请号：US10618126

申请日：2003-07-11

申请人： Wayne A. Froland ,  Drew N. Kelner ,  Michael L. Dumas ,  Clark Pan ,  James Whelan ,  Yu-chang John Wang ,  Wei Wang

发明人： Wayne A. Froland ,  Drew N. Kelner ,  Michael L. Dumas ,  Clark Pan ,  James Whelan ,  Yu-chang John Wang ,  Wei Wang

IPC分类号： C07K14/705

CPC分类号： C07K14/70503 ,  A61K38/00 ,  C07K14/57563

摘要： This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides are shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptides of this invention are also stable in formulation and have long half-lives. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VPAC2-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.

摘要翻译： 本发明提供了在体内作为VPAC2受体的激动剂起作用的新型肽。 显示这些胰岛素促分泌素多肽比葡萄糖攻击时的对照降低体内血糖。 本发明的多肽在制剂中也是稳定的并且具有长的半衰期。 本发明的肽为具有降低的内源性胰岛素分泌的患者特别是2型糖尿病患者提供了新的疗法。 特别地，本发明是选自VPAC2相关多肽的特定组的多肽或其功能等同物。 本发明还涉及一种治疗哺乳动物代谢疾病的方法，包括向所述哺乳动物施用治疗有效量的胰岛素促分泌肽。 还公开了制备重组体和合成肽的方法。